
 
 
 
 
 
 
 
 
  What is Claimed is: 
 
 1. An isolated nucleic acid sequence encoding epothilone B hydroxylase or a mutant or variant thereof. 
 
 
 2. The isolated nucleic acid sequence of claim 1 comprising SEQ ID NO: 1, 30, 32, 34, 36, 37, 38, 39, 40, 41, 42, 60, 62, 64, 66, 68, 72 or 74. 
 
 
 3. The isolated nucleic acid sequence of claim 1 comprising SEQ ID NO:l. 
 
 
 4. The isolated nucleic acid sequence of claim 1 encoding a mutant with at least one amino acid substitution in an active site of the epothilone B hydroxylase enzyme. 
 
 
 5. The isolated nucleic acid sequence of claim 1 encoding a mutant with at least one amino acid substitution at amino acid GLU31, ARG67, ARG88, ILE92, ALA93, VAL106, ILE130, ALAMO, MET176, PHE190, GLU 231, SER294, PHE237, or ILE365 of SEQ ID NO:2. 
 
 
 6. The isolated nucleic acid sequence of claim 1 encoding a mutant with at least one amino acid substitution at amino acid LEU39, GLN43, ALA45, MET57, LEU58, HIS62, PHE63, SER64, SER65, ASP66, ARG67, GLN68, SER69, LEU74, MET75, VAL76, ALA77, ARG78, GLN79, ILE80, ASP84, LYS85, PRO86, PHE87, ARG88, PRO89, SER90, LEU91, ELE92, ALA93, MET94, ASP95, HIS99, ARG103, PHE110, ILE155, PHE169, GLN170, CYS172, SER173, SER174, ARG175, MET176, LEU177, SER178, ARG179, ARG186, PHE190, LEU193, VAL233, GLY234, LEU235, ALA236, PHE237, LEU238, LEU239, LEU240, ILE241, ALA242, GLY243, HIS244, GLU245, THR246, THR247, ALA248, ASN249, MET250, LEU283, THR287, ILE288, ALA289, GLU290, THR291, ALA292, THR293, SER294, ARG295, PHE296, ALA297, THR298, GLU312, GLY313, VAL314, VAL315, GLY316, VAL344, ALA345, PHE346, GLY347, PHE348, VAL350, HIS351, GLN352, CYS353, LEU354, GLY355, GLN356, LEU358,  ALA359, GLU362, LYS389, ASP391, SER392, THR393, B E394, or TYR395 of SEQ ID NO:2. 
 
 
 7. Tfie isolated nucleic acid sequence of claim 1 encoding a variant comprising SEQ ID NO:43, 44, 45, 46, 47, 48 or 49. 
 
 
 8. A polypeptide encoded by the isolated nucleic acid sequence of claim 1. 
 
 
 9. An isolated nucleic acid molecule that is capable of hybridizing to a nucleic acid sequence of claim 2, or to the complementary sequence of said nucleic acid sequence, under hybridization conditions of 3X SSC at 65 째C for 16 hours, said isolated nucleic acid molecule being capable of remaining hybridized to said nucleic acid sequence, or to the complementary sequence of said nucleic acid sequence, under wash conditions of 0.5X SSC, 55째C for 30 minutes. 
 
 
 10. An isolated polypeptide comprising SEQ ID NO:2. 
 
 
 11. An isolated mutant polypeptide of epothilone B hydroxylase of SEQ 
 ID NO:2 comprising an amino acid sequence with at least one amino acid substitution in an active site of epothilone B hydroxylase enzyme of SEQ ID NO: 2. 
 
 
 12. An isolated mutant polypeptide of epothilone B hydroxylase of SEQ ID NO: 2 comprising an amino acid sequence with at least one amino acid substitution at amino acid GLU31, ARG67, ARG88, ILE92, ALA93, VAL106, ILE130, ALA140, MET176, PHE190, GLU 231, SER294, PHE237, or H E365 of SEQ ID NO:2. 
 
 
 13. An isolated mutant polypeptide of epothilone B hydroxylase of SEQ 
 ID NO: 2 comprising an amino acid sequence with at least one amino acid substitution at amino acid LEU39, GLN43, ALA45, MET57, LEU58, HIS62, PHE63, SER64, SER65, ASP66, ARG67, GLN68, SER69, LEU74, MET75, VAL76, ALA77, ARG78, GLN79, ILE80, ASP84, LYS85, PRO86, PHE87, ARG88, PRO89, SER90, LEU91, ILE92, ALA93, MET94, ASP95, HIS99, ARG103, PHE110, ILE155,  PHE169, GLN170, CYS172, SER173, SER174, ARG175, MET176, LEU177, SER178, ARG179, ARG186, PHE190, LEU193, VAL233, GLY234, LEU235, ALA236, PHE237, LEU238, LEU239, LEU240, ILE241, ALA242, GLY243, HIS244, GLU245, THR246, THR247, ALA248, ASN249, MET250, LEU283, THR287, ILE288, ALA289, GLU290, THR291, ALA292, THR293, SER294, ARG295, PHE296, ALA297, THR298, GLU312, GLY313, VAL314, VAL315, GLY316, VAL344, ALA345, PHE346, GLY347, PHE348, VAL350, HIS351, GLN352, CYS353, LEU354, GLY355, GLN356, LEU358, ALA359, GLU362, LYS389, ASP391, SER392, THR393, ILE394, or TYR395 of SEQ ID NO:2. 
 
 
 14. An isolated mutant polypeptide of epothilone B hydroxylase comprising SEQ ID NO: 31, 33, 35, 61, 63, 65, 67, 69, 71, 73 or 75. 
 
 
 15. An isolated variant polypeptide of epothilone B hydroxylase comprising SEQ ID NO: 43, 44, 45, 46, 47, 48 or 49. 
 
 
 16. An isolated nucleic acid sequence encoding a ferredoxin. 
 
 
 17. The isolated nucleic acid sequence of claim 16 comprising SEQ ID NO:3. 
 
 
 18. A polypeptide encoded by the isolated nucleic acid sequence of claim 16.  
 
 
 19. An isolated nucleic acid molecule that is capable of hybridizing to the nucleic acid sequence set forth in SEQ ID NO:3, or to the complementary sequence of the nucleic acid sequence set forth in SEQ ID NO: 3, under hybridization conditions of 3X SSC at 65 째C for 16 hours, said isolated nucleic acid molecule being capable of remaining hybridized to the nucleic acid sequence set forth in SEQ ID NO: 3, or to the complementary sequence of the nucleic acid sequence set forth in SEQ ID NO: 3, under wash conditions of 0.5X SSC, 55째C for 30 minutes. 
 
 
 20. A vector comprising the isolated nucleic acid sequence of claim 1. 
 
 
 21. The vector of claim 20 further comprising an isolated nucleic acid sequence encoding a ferredoxin.   
 
 
 22. A host cell comprising the vector of claim 20. 
 
 
 23. A host cell comprising the vector of claim 21. 
 
 
 24. A method for producing recombinant microorganisms which hydroxylate epothilones having a terminal alkyl group to produce epothilones having a terminal hydroxyalkyl group, said method comprising transfecting a microorganism with the vector of claim 20 or 21. 
 
 
 25. A recombinantly produced microorganism that hydroxylates epothilones having a terminal alkyl group to produce epothilones having a terminal hydroxyalkyl group. 
 
 
 26. The recombinantly produced microorganism of claim 25 wherein said microorganism expresses a nucleic acid sequence of SEQ ID NO: 1, 30, 32, 34, 36, 37, 38, 39, 40, 41, 42, 60, 62, 64, 66, 68, 72 or 74. 
 
 
 27. A method for the preparation of at least one epothilone of the following formula I 
 HO-CH 2 -(A  n -(Q) m -(A 2 ) o -E (I) where 
 Ai and A 2  are independently selected from the group of optionally substituted Ci-C 3  alkyl and alkenyl; Q is an optionally substituted ring system containing one to three rings and at least one carbon to carbon double bond in at least one ring; n, m, and o are integers selected from the group consisting of zero and 1, where at least one of m or n or o is 1 ; and E is an epothilone core; comprising the steps of contacting at least one epothilone of the following formula II 
 CH 3 -(A 1 ) n -(Q) ra -(A 2 ) o -E (II) where A , Q, A 2 , E, n, m, and o are defined as above;  with a recombinantly produced microorganism, or an enzyme derived therefrom, which is capable of selectively catalyzing the hydroxylation of Formula II, and effecting said hydroxylation. 
 
 
 28. A method for the preparation of an epothilone analog of Formula A 
 
 
 
 said method comprising biotransforming epothilone B to the epothilone analog of Formula A by incubation with a mutant epothilone B hydroxylase enzyme comprising SEQ ID NO:31. 
 
 
 29. A compound of Formula A 
 
 
 
 or a pharmaceutically acceptable salt thereof. 
 
 
 30. A homology model of epothilone B hydroxylase having a root mean square deviation of conserved residue backbone atoms of less than about 4.0 A when superimposed on a corresponding backbone atoms described by structure coordinates listed in Appendix 1.   
 
 
 31. A method for producing a mutant with altered biological properties, function, yield of a desired product, rate of reaction, substrate specificity, or activity as compared to epothilone B hydroxylase, said method comprising the steps of: identifying an amino acid of SEQ ID NO:2 to mutate; and mutating the identified amino acid to create a mutant protein. 
 
 
 32. The method of claim 31 wherein a homology model of epothilone B hydroxylase having a root mean square deviation of conserved residue backbone atoms of less than about 4.0 A when superimposed on a corresponding backbone atoms described by structure coordinates listed in Appendix 1 is used to identify an amino acid of SEQ ID NO: 2 to mutate. 
 
 
 33. The method of claim 31 wherein the identified amino acid is LEU39, GLN43, ALA45, MET57, LEU58, HIS62, PHE63, SER64, SER65, ASP66, ARG67, GLN68, SER69, LEU74, MET75, VAL76, ALA77, ARG78, GLN79, ILE80, ASP84, LYS85, PRO86, PHE87, ARG88, PRO89, SER90, LEU91, ILE92, ALA93, MET94, ASP95, HIS99, ARG103, PHE110, ILE155, PHE169, GLN170, CYS172, SER173, SER174, ARG175, MET176, LEU177, SER178, ARG179, ARG186, PHE190, LEU193, VAL233, GLY234, LEU235, ALA236, PHE237, LEU238, LEU239, LEU240, ILE241, ALA242, GLY243, HIS244, GLU245, THR246, THR247, ALA248, ASN249, MET250, LEU283, THR287, ILE288, ALA289, GLU290, THR291, ALA292, THR293, SER294, ARG295, PHE296, ALA297, THR298, GLU312, GLY313, VAL314, VAL315, GLY316, VAL344, ALA345, PHE346, GLY347, PHE348, VAL350, HIS351, GLN352, CYS353, LEU354, GLY355, GLN356, LEU358, ALA359, GLU362, LYS389, ASP391, SER392, THR393, ILE394, or TYR395 of SEQ ID NO:2. 
 
 
 34. The method of claim 31 wherein the identified amino acid is GLU31, ARG67, ARG88, ILE92, ALA93, VAL106, ILE130, ALAMO, MET176, PHE190, GLU 231 , SER294, PHE237, or ILE365 of SEQ ID NO:2.   
 
 
 35. The method of claim 31 wherein the mutant protein improves yield of a desired product as compared to the yield of a desired product obtained using epothilone B hydroxylase. 
 
 
 36. The method of claim 35 wherein the desired product is epothilone F. 
 
 
 37. The method of claim 31 wherein the mutant improves the rate of reaction as compared to the rate of reaction using epothilone B hydroxylase. 
 
 
 38. The method of claim 31 wherein the mutant exhibits altered substrate specificity as compared to substrate specificity of epothilone B hydroxylase. 
 
 
 39. The method of claim 38 wherein amino acid SER294 is mutated. 
 
 
 40. The method of claim 31 wherein the mutant exhibits essentially similar biological activity or function to epothilone B hydroxylase. 
 
 
 41. A machine-readable data storage medium comprising a data storage material encoded with structure coordinates set forth in Appendix 1.  
 
 
 
 
 
 
 
 
 
 
